Lorazepam

Generic Name: Lorazepam

Brand Names: Ativan, Loreev

Drug Type: Small Molecule

Chemical Formula: C_₁₅H_₁₀Cl_₂N_₂O_₂

CAS Number: 846-49-1

Unique Ingredient Identifier: O26FZP769L

Background: Lorazepam is a short-acting and rapidly cleared benzodiazepine used commonly as a sedative and anxiolytic. It was developed by DJ Richards, presented and marketed initially by Wyeth Pharmaceuticals in the USA in 1977. The first historic FDA label approval is reported in 1985 by the company Mutual Pharm.

Indication: Lorazepam is FDA-approved for the short-term relief of anxiety symptoms related to anxiety disorders and anxiety associated with depressive symptoms such as anxiety-associated insomnia. It is as well used as an anesthesia premedication in adults to relieve anxiety or to produce sedation/amnesia and for the treatment of status epilepticus.

Some off-label indications of lorazepam include rapid tranquilization of an agitated patient, alcohol withdrawal delirium, alcohol withdrawal syndrome, muscle spasms, insomnia, panic disorder, delirium, chemotherapy-associated anticipatory nausea and vomiting, and psychogenic catatonia.

Associated Conditions: Agitation, Alcohol Withdrawal Delirium, Alcohol Withdrawal Syndrome, Anxiety, Anxiety Disorders, Chemotherapy-Induced Nausea and Vomiting, Delirium, Insomnia, Muscle Spasms, Panic Disorder, Psychogenic Catatonia, Status Epilepticus

Associated Therapies: Anesthetic premedication therapy

Clinical Trials

Exploring the Effects of Diazepam and Lorazepam

Not Applicable

Completed

Conditions: Healthy Subjects

Interventions: Drug: Lorazepam
Drug: Diazepam
Drug: placebo

First Posted Date: 2008-06-12

Last Posted Date: 2009-09-17

Lead Sponsor: University Hospital, Strasbourg, France

Target Recruit Count: 22

Registration Number: NCT00696033

Locations: 🇫🇷
Centre d'investigation clinique, hôpital civil, Strasbourg, France
🇫🇷
Clinique psychiatrique, hôpital civil, Strasbourg, France

Fasting Study of Lorazepam Tablets 2 mg and Ativan Tablets 2 mg

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Lorazepam Tablets 2 mg
Drug: Ativan Tablets 2 mg

First Posted Date: 2008-04-01

Last Posted Date: 2024-04-24

Lead Sponsor: Mylan Pharmaceuticals Inc

Target Recruit Count: 28

Registration Number: NCT00649818

Locations: 🇺🇸
Kendle International Inc., Morgantown, West Virginia, United States

Treating Benign Paroxysmal Positional Vertigo (BPPV) in ED Patients

Not Applicable

Completed

Conditions: Benign Paroxysmal Positional Vertigo

Interventions: Other: Epley Maneuver
Drug: Meclizine
Drug: Lorazepam
Drug: Diphenhydramine
Drug: Ondansetron

First Posted Date: 2008-03-24

Last Posted Date: 2018-04-03

Lead Sponsor: Lehigh Valley Hospital

Target Recruit Count: 26

Registration Number: NCT00641797

Locations: 🇺🇸
Lehigh Valley Hospital, Allentown, Pennsylvania, United States

Safety and Efficacy Evaluation Of Pregabalin (Lyrica) With Patients With Generalized Anxiety Disorder

Phase 4

Completed

Conditions: Generalized Anxiety Disorder

Interventions: Drug: Pregabalin
Drug: Placebo
Drug: Lorazepam

First Posted Date: 2008-02-27

Last Posted Date: 2021-01-28

Lead Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Target Recruit Count: 615

Registration Number: NCT00624780

Locations: 🇹🇷
Pfizer Investigational Site, Kocaeli, Turkey

Efficacy and Safety Study Comparing Lorazepam and Diazepam for Children in the Emergency Department With Seizures (Status 2)

Phase 2

Completed

Conditions: Status Epilepticus

Interventions: Drug: lorazepam or diazepam

First Posted Date: 2008-02-22

Last Posted Date: 2012-12-18

Lead Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Target Recruit Count: 259

Registration Number: NCT00621478

Locations: 🇺🇸
Children's Hospital Colorado, Aurora, Colorado, United States
🇺🇸
Children's Hospital of Michigan, Detroit, Michigan, United States
🇺🇸
University of Michigan Emergency Medicine Research, Ann Arbor, Michigan, United States

and more 11 locations

Treating Alcohol Withdrawal With Oral Baclofen

Not Applicable

Completed

Conditions: Alcohol Withdrawal Delirium

Interventions: Drug: Placebo
Drug: Baclofen
Drug: Lorazepam

First Posted Date: 2008-01-18

Last Posted Date: 2011-07-27

Lead Sponsor: Essentia Health

Target Recruit Count: 79

Registration Number: NCT00597701

Locations: 🇺🇸
Essentia Health, Duluth, Minnesota, United States

The Impact of Lorazepam on Cognition in APOE e4 Carriers

Not Applicable

Completed

Conditions: Alzheimer's Disease

Interventions: Drug: placebo
Drug: lorazepam

First Posted Date: 2008-01-04

Last Posted Date: 2008-01-04

Lead Sponsor: Mayo Clinic

Target Recruit Count: 36

Registration Number: NCT00586430

Locations: 🇺🇸
Mayo Clinic, Scottsdale, Arizona, United States

A Comparison of Lorazepam and Diazepam in the Treatment of Alcohol Withdrawal

Not Applicable

Completed

Conditions: Alcohol Withdrawal

Interventions: Drug: Lorazepam
Drug: Diazepam

First Posted Date: 2007-08-31

Last Posted Date: 2007-08-31

Lead Sponsor: Stanford University

Target Recruit Count: 55

Registration Number: NCT00523185

Locations: 🇺🇸
Palo Alto Veterans Affairs Hospital System, Palo Alto, California, United States
🇺🇸
Stanford Hospital and Clinics, Stanford, California, United States